45 results
8-K
EX-99.1
OGEN
Oragenics Inc
5 Jun 23
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
4:30pm
such as this accelerate technological advancement by combining the most innovative R&D from each organization,” said Diane Gosselin, President and CEO of CQDM
8-K
EX-99.2
mlaxgwt3
9 Mar 21
Regulation FD Disclosure
7:15am
8-K
0bot0z pdzi4xl29gd3
2 Dec 13
Departure of Directors or Certain Officers
12:00am
8-K
b2ewgql
22 Oct 13
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
x31ywz
12 Sep 13
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
12:00am
8-K
EX-99.1
pkinb70cpua
7 Jul 10
Oragenics Announces Entering into Agreement to provide $2.0MM Equity
12:00am